Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
J Appl Clin Med Phys. 2013 Jul 8;14(4):4182. doi: 10.1120/jacmp.v14i4.4182.
Radiochromic and radiographic films are widely used for radiation dosimetry due to the advantage of high spatial resolution and two-dimensional dose measurement. Different types of scanners, including various models of flatbed scanners, have been used as part of the dosimetry readout procedure. This paper focuses on the characterization of the EBT2 film response in combination with a Microtek ScanMaker 9800XL scanner and the subsequent use in the dosimetric verification of a 3D conformal radiotherapy treatment. The film reproducibility and scanner uniformity of the Microtek ScanMaker 9800XL was studied. A three-field 3D conformal radiotherapy treatment was planned on an anthropomorphic phantom and EBT2 film measurements were carried out to verify the treatment. The interfilm reproducibility was found to be 0.25%. Over a period of three months, the films darkened by 1%. The scanner reproducibility was ± 2% and a nonuniformity was ±1.9% along the direction perpendicular to the scan direction. EBT2 measurements showed an underdose of 6.2% at high-dose region compared to TPS predicted dose. This may be due to the inability of the treatment planning system to predict the correct dose distribution in the presence of tissue inhomogeneities and the uncertainty of the scanner reproducibility and uniformity. The use of EBT2 film in conjunction with the axial CT image of the anthropomorphic phantom allows the evaluation of the anatomical location of dose discrepancies between the EBT2 measured dose distribution and TPS predicted dose distribution.
放射色迹和射线照相胶片由于具有高空间分辨率和二维剂量测量的优势,因此被广泛用于辐射剂量测定。不同类型的扫描仪,包括各种平板扫描仪型号,已被用作剂量读出程序的一部分。本文重点介绍 EBT2 胶片响应与 Microtek ScanMaker 9800XL 扫描仪相结合的特性,以及随后在 3D 适形放射治疗剂量验证中的应用。研究了 Microtek ScanMaker 9800XL 的胶片再现性和扫描仪均匀性。在人体模型上规划了三个野的 3D 适形放射治疗,并进行了 EBT2 胶片测量以验证治疗。胶片之间的再现性为 0.25%。在三个月的时间里,胶片的灰度增加了 1%。扫描仪的再现性为±2%,沿垂直于扫描方向的方向不均匀度为±1.9%。EBT2 测量结果显示,与 TPS 预测剂量相比,高剂量区域的剂量不足 6.2%。这可能是由于治疗计划系统无法在存在组织不均匀性的情况下预测正确的剂量分布,以及扫描仪再现性和均匀性的不确定性。EBT2 胶片与人体模型的轴向 CT 图像结合使用,可以评估 EBT2 测量的剂量分布与 TPS 预测的剂量分布之间的剂量差异的解剖位置。